pm mfvt1
    • Main page
      • About journal
      • Articles. Working with contents
      • Editor-in-chief
      • Editorial Council
      • Editorial Board


      • For authors
      • Standards for formatting information
      • Reviewing
      • Politics editorial board
      • Ethics of journal publications


      • For advertisers
      • Subscription
      • About the Publishing House
      • Contact us
  • The case of omalizumab use in treatment of severe persistent asthma

    Редакция | 2014, Clinical case, Practical medicine 07 (14) Infectious diseases. Antimicrobial therapy | 7 октября, 2014

    V.I. ILYINSKIY¹, O.V. SKOROKHODKINA², A.R. VALEEVA²

    ¹Republican Clinical Hospital, 138 Orenburgskiy tract, Kazan, Russian Federation, 420064

    ²Kazan State Medical University, 49 Butlerov St., Kazan, Russian Federation, 420012

    Ilyinskiy V.I. — Head of the Department of Pulmonology, tel. +7-987-296-26-13, e-mai: [email protected]1

    Skorokhodkina O.V. — D. Med. Sc., Professor of the Department of Clinical Immunology and Allergology, tel. +7-917-392-50-45, e-mail: [email protected]2

    Valeeva A.R. — Resident Doctor of the Department of Clinical Immunology and Allergology, tel. +7-917-911-70-10, e-mail: [email protected]2

    The article presents results of clinical observation of a patient with severe persistent allergic asthma treated with omalizumab. Omalizumab is a treatment option for patients with moderate to severe allergic asthma in cases when the symptoms are poorly controlled with inhaled corticosteroids. Treatment with omalizumab resulted in improvement of both the disease symptoms and respiratory function indicators. It is concluded that the addition of omalizumab decreases the doses of corticosteroids and allows to achieve control over the disease.

    Key words: severe persistent allergic asthma, omalizumab.

     

     

    REFERENCES

    1. Kolbin A.S., Klimko N.N., Andreev B.V. Clinical and economic rationale for the use Xolair (omalizumab) in bronchial asthma.Kachestvennaya klinicheskaya praktika, 2008, no. 2, pp. 53-61 (in Russ.).

    2. Global Initiative for Asthma. Workshop Report, 2011.

    3. Soler M., Matz J., Townley R. et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics.Eur Respir. J., 2001, 18, rr. 254 261.

    4. Burkovskaya E.N. New approaches to the treatment of severe asthma.Novye metody diagnostiki i lecheniya, 2008, no. 1, pp. 53-56 (in Russ.).

    5. Knyazheskaya N.P. Ksolar (omalizumab) v terapii bronkhial’noy astmy [Xolair (omalizumab) in the treatment of bronchial asthma]Pul’monologiya detskogo vozrasta: problemy i resheniya. Moscow, 2007. Issue 7. Pp. 151-153.

    Метки: A.R. VALEEVA, O.V. SKOROKHODKINA, omalizumab, Practical medicine 07 (14) Infectious diseases. Antimicrobial therapy, severe persistent allergic asthma, V.I. ILYINSKIY

    ‹ Diagnosis of rabies (clinical case) Cardiologic heritage of s.s. Zimnitskiy (to the 140th anniversary of s.s. Zimnitskiy) ›
    • rus Версия на русском языке


      usa English version site


      Findloupe

      

    • PARTNERS

      пов  logonew
    «Для
    Practical medicine. Scientific and practical reviewed medical journal
    All rights reserved ©